My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

18.46 +0.09 (+0.49%)

Official Closing Price Updated: 7:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Takeda's Dengue Vaccine Gets WHO Approval, Eligible for UN Procurement ↗

May 15, 2024

Takeda's dengue vaccine, Qdenga, gains WHO prequalification, enabling UN agency procurement. Approved in multiple countries, Qdenga is recommended for children 6-16 in high dengue areas.

Via Benzinga

Why Is Small-Cap Alzheimer's-Focused AC Immune Stock Trading Higher On Monday? ↗

May 13, 2024

Unlocking hope for Alzheimer's with ACI-24.060. Takeda's agreement with AC Immune targets toxic forms of Abeta, potentially slowing disease progression.

Via Benzinga

Why Is AC Immune (ACIU) Stock Up 45% Today? ↗

May 13, 2024

AC Immune stock is up on Monday after as investors in ACIU react to a new collaboration agreement with Takeda Pharmaceutical.

Via InvestorPlace

Catalyst's New CEO Has Big Ideas For The Small Biotech ↗

May 10, 2024

Richard Daly is Catalyst Pharmaceuticals' second CEO, taking over for Patrick McEnany, who retired last year.

Via Investor's Business Daily

Japan's Takeda Pharma Outlines $900M Overhaul To Boost Growth, As 2023 Profit Fall Over 50% ↗

May 09, 2024

Takeda Pharmaceutical (NYSE: TAK) reveals fiscal year 2023 results & restructuring plan. Revenue up 5.9%, net profit down 54.6%. Expecting operating profit of 225 billion yen in 2024.

Via Benzinga

Looking Into Takeda Pharmaceutical's Recent Short Interest ↗

January 15, 2024

Via Benzinga

(TAK) - Analyzing Takeda Pharmaceutical's Short Interest ↗

December 25, 2023

Via Benzinga

(TAK) - Analyzing Takeda Pharmaceutical's Short Interest ↗

December 07, 2023

Via Benzinga

Peering Into Takeda Pharmaceutical's Recent Short Interest ↗

November 21, 2023

Via Benzinga

TAK Stock Earnings: Takeda Pharmaceutical Reported Results for Q4 2023 ↗

May 09, 2024

Takeda Pharmaceutical just reported results for the fourth quarter of 2023.

Via InvestorPlace

Neurocrine Biosciences Says Treatment Can Alleviate Several Symptoms Associated With Depressive Disorder ↗

April 23, 2024

Neurocrine Biosciences reports Phase 2 data for NBI-1065845 in major depressive disorder. Results show significant improvement in MADRS scores. William Blair sees the potential for $1 billion+ in...

Via Benzinga

No. 1 Biotech Stock Neurocrine Launches Higher On Depression Treatment Win ↗

April 23, 2024

The company is establishing its line-up of drugs behind bread-and-butter med Ingrezza.

Via Investor's Business Daily

The Hot List: 3 AI Stocks Worth Buying on Weakness ↗

March 01, 2024

Firms using AI directly can be great picks for long-term investors, such as these three AI stocks to buy on weakness.

Via InvestorPlace

Topics Artificial Intelligence

FDA Approves Takeda's Eohilia As First Oral Treatment For Inflammed Esophagus ↗

February 12, 2024

Eohilia: FDA-approved oral therapy for EoE. Takeda's innovative 2mg/10mL stick packs available by February. Histologic remission achieved in studies.

Via Benzinga

Looking Into Takeda Pharmaceutical's Recent Short Interest ↗

November 03, 2023

Via Benzinga

Good News For Sleep Disorder Patients - Takeda's Therapy Shows Promise In Mid-Stage Study ↗

February 09, 2024

Takeda's Phase 2b trial results for TAK-861, an oral orexin receptor 2 agonist, in narcolepsy type 1 patients. Global Phase 3 trials planned for fiscal year 2024.

Via Benzinga

Why Is Japanese Drugmaker Takeda Stock Trading Lower Today? ↗

February 01, 2024

Takeda Pharmaceutical's Q3 2023 results: ¥235.9 billion core net profit, management changes, and a global collaboration deal for rusfertide. Fiscal year 2023 guidance reiterated.

Via Benzinga

3 Stocks to Buy to Benefit From the Booming Sleep Industry ↗

January 23, 2024

It’s not easy to find sleep stocks to buy despite the fact the industry is booming these days from society's lack of rest and relaxation.

Via InvestorPlace

Week In Review: China Biopharmas Book $9 Billion In Deals During JP Morgan Conference Week ↗

January 13, 2024

Shanghai Argo Biopharma entered 2 agreements with Novartis, out-licensing four next-gen RNAi therapeutics for $185 million upfront and a total value of $4.2 billion. Additionally, Ambrx Biopharma will...

Via Talk Markets

More Than 140 Drug Brands Will Have Their Prices Hiked Heading Into 2024 ↗

January 04, 2024

More than 140 brands of drugs are going to see their prices hiked heading into the new year

Via Talk Markets

Earnings Scheduled For February 1, 2024 ↗

February 01, 2024

Companies Reporting Before The Bell • ING Groep (NYSE:ING) is expected to report earnings for its fourth quarter. • Shell (NYSE:SHEL) is likely to report quarterly earnings at $1.81 per share on...

Via Benzinga

Expensive Drugs For Americans In 2024? Drugmakers Including Pfizer, Sanofi Mull Price Increase In January ↗

December 29, 2023

Just as large pharma companies prepare a showdown with Medicare's newfound power to negotiate down drug prices, several major drug companies are reportedly gearing up to implement price increases on...

Via Benzinga

One Ultra-Cheap High-Yield Dividend Stock to Buy ↗

December 22, 2023

Now may be a good time for dividend investors to consider loading up on this stock.

Via The Motley Fool

Ionis' Strategic Shift Praised by Analysts For Donidalorsen's Global Reach ↗

December 19, 2023

Monday, Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered into a license agreement with Otsuka Pharmaceutical Co Ltd under which Otsuka obtains exclusive rights in Europe to commercialize donidalorsen,...

Via Benzinga

Why Is Neurocrine Biosciences Stock Trading Lower Today? ↗

November 10, 2023

Thursday, Neurocrine Biosciences Inc (NASDAQ: NBIX)

Via Benzinga

Back To Back FDA Approval For Takeda Within Two Days, Secures Green Signal For Rare Blood Disorder Therapy ↗

November 10, 2023

The FDA approved Takeda Pharmaceutical Co Ltd's (NYSE:

Via Benzinga

3 Promising Biotech Stocks Flying Under the Radar ↗

November 08, 2023

Breakthroughs in healthcare are happening everyday, make sure you are keeping up to date on these under the radar biotech stocks.

Via InvestorPlace

Earnings Scheduled For October 26, 2023 ↗

October 26, 2023

Companies Reporting Before The Bell • TotalEnergies (NYSE:TTE) is likely to report quarterly earnings at $2.57 per share on revenue of $49.83 billion.

Via Benzinga

Alkermes Plummets In Huge Volume. Why One Analyst Says The Reaction Is Overdone. ↗

October 23, 2023

Analysts say Alkermes' drug is clearly active. But investors have concerns.

Via Investor's Business Daily

Week In Review: China's Biopharmas Announce $2.5 Billion In Deals ↗

October 21, 2023

KBP Biosciences sold global rights for its hypertension candidate to Novo Nordisk in an agreement worth up to $1.3 billion. Also, EpimAb Bio sold the rights to use its Fabs-In-Tandem Immunoglobulin...

Via Talk Markets

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.